| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
D-Alanine-d7 targets the inhibitory glycine receptor (GlyR) and PMBA, where it acts as a weak agonist. D-Alanine has an EC₅₀ for GlyR of 9 mM. D-Alanine is also involved in bacterial cell wall synthesis, where it is incorporated into peptidoglycan. The deuterated form is used to study D-alanine metabolism and its role in neurotransmission and bacterial physiology.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, D-Alanine-d7 is used as a tracer to study D-alanine metabolism and GlyR activation. The compound is incorporated into cell culture media to track amino acid uptake and metabolism. It serves as a quantitative tool for studying cellular metabolism, neurotransmission, and bacterial cell wall synthesis. D-Alanine is a weak agonist of GlyR with an EC₅₀ of 9 mM. |
| ln Vivo |
In vivo, D-Alanine-d7 is used in metabolic studies to trace the absorption, distribution, metabolism, and excretion of D-alanine. The deuterium label allows for precise quantification of the compound and its metabolites in biological fluids and tissues using mass spectrometry. It is used in research on neurotransmission and bacterial infections.
|
| Enzyme Assay |
As an analytical standard, D-Alanine-d7 is used in amino acid analysis and metabolomics studies. Typical protocols involve spiking the labeled compound into samples prior to analysis by GC-MS or LC-MS. The compound serves as an internal standard to correct for matrix effects and instrument variability.
|
| Cell Assay |
In vitro cell culture experiments using D-Alanine-d7 involve supplementing growth media with the labeled compound at defined concentrations. Cells are cultured for specified periods, after which the metabolism of the compound is analyzed by mass spectrometry. The compound can also be used to study amino acid transport and metabolism in various cell types.
|
| Animal Protocol |
In vivo animal studies using D-Alanine-d7 typically involve administering the compound to rodents via oral gavage or intravenous injection. Blood, urine, and tissue samples are collected at various time points to track the distribution and metabolism of the compound. The deuterium label allows for precise quantification using mass spectrometry.
|
| ADME/Pharmacokinetics |
D-Alanine-d7 exhibits pharmacokinetic properties similar to those of unlabeled D-alanine. As an amino acid, it is absorbed from the gastrointestinal tract and distributed throughout the body. It is metabolized primarily in the liver and kidneys. The deuterium label provides a distinct mass shift for analytical detection without significantly altering the compound's physicochemical properties.
|
| Toxicity/Toxicokinetics |
D-Alanine-d7 is considered safe for research use at typical concentrations. The compound is non-hazardous for transport and stable if stored under recommended conditions. As a stable isotope-labeled compound, it is not intended for therapeutic use and is handled under standard laboratory safety practices.
|
| References |
|
| Additional Infomation |
D-Alanine-d7 has a molecular formula of C₃D₇NO₂ and a molecular weight of 96.14. Enantiomeric purity is 99%. The compound is soluble in water (165 mg/mL) and is stored at -20°C. It is primarily used as an internal standard for mass spectrometry-based quantification of D-alanine in metabolomics and bacterial research.
|
| Molecular Formula |
C3H7NO2
|
|---|---|
| Molecular Weight |
89.09
|
| Exact Mass |
96.091
|
| CAS # |
2483831-62-3
|
| Related CAS # |
D-Alanine;338-69-2
|
| PubChem CID |
162343529
|
| Appearance |
White to off-white solid powder
|
| LogP |
-3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
6
|
| Complexity |
61.8
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[C@@]([H])(N([H])[H])(C([H])([H])[H])C(=O)O[H]
|
| InChi Key |
QNAYBMKLOCPYGJ-VETUMQINSA-N
|
| InChi Code |
InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m1/s1/i1D3,2D/hD3
|
| Chemical Name |
deuterio (2R)-2,3,3,3-tetradeuterio-2-(dideuterioamino)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~165 mg/mL (~1716.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 11.2246 mL | 56.1230 mL | 112.2460 mL | |
| 5 mM | 2.2449 mL | 11.2246 mL | 22.4492 mL | |
| 10 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
